Biohaven announced plans to initiate pivotal clinical trials mid-2026 for its novel protein degrader therapies targeting IgA nephropathy and Graves' disease. The company expects topline results in the second half of 2026 from its epilepsy program using a selective Kv7 ion channel activator and from a Phase 2 obesity study with a myostatin-activin pathway inhibitor. Additional progress includes ongoing trials in early Parkinson's disease and advanced endometrial cancer, with no major safety issues reported. Biohaven reported a reduced net loss in Q1 2026 and maintains a strong cash position of approximately $352 million, positioning it well for upcoming milestones and continued development across its neuroscience, immunology, and oncology pipeline.
Valeo SE disclosed the total number of voting rights and shares forming its share capital as of June 30, 2026. The company reported 245.6 million shares with a par value of €1 each, totaling 276.9 million theoretical voting rights and 272.8 million e...
Valeo has disclosed the total number of voting rights and shares composing its share capital as of June 30, 2026. The company reported a capital of €245,607,624 with 245,607,624 shares, theoretical voting rights totaling 276,898,916, and exercisable ...
A three-day online training on Pharmaceutical Regulatory Affairs in Asia is scheduled for October 20-22, 2026, aiming to help professionals understand diverse regulatory requirements across major Asian markets including China, India, Korea, and ASEAN...
The global workwear market, valued at $265.12 billion in 2025, is expected to grow to $344.71 billion by 2031 with a 4.5% CAGR. Growth is fueled by rising corporate employment worldwide, especially in Asia-Pacific, and increased focus on professional...
The global microalgae-based aquafeed market is projected to grow from $320 million in 2026 to $481 million by 2031, at an 8.5% CAGR. Key growth drivers include rapid cost reductions in closed photobioreactor farming, making algae competitive with fis...
